The purpose of this study is to evaluate the effect of deucravacitinib on quality of life (QoL) in participants with plaque psoriasis in a community setting.
Condition or Disease
|Double (Participant, Investigator)
|A Study to Evaluate the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting
|Actual Study Start Date:
|Estimated Primary Completion Date:
|Estimated Study Completion Date:
|Ages Eligible for Study:
|18 Years and older (Adult, Older Adult)
|Sexes Eligible for Study:
|Accepts Healthy Volunteers:
Men and women diagnosed with stable plaque psoriasis for 6 months or more. Stable psoriasis is defined as no morphology changes or significant flares of disease activity in the opinion of the investigator. Deemed by the investigator to be a candidate for phototherapy or systemic therapy. ≥ 3% of Body Surface Area (BSA) involvement at Screening Visit and Day 1 Dermatology Life Quality Index (DLQI) score > 5 at Screening Visit and Day 1
Target Disease Exceptions: Non-plaque psoriasis (that is, guttate, pustular, erythrodermic, palmoplantar only involvement or drug-induced psoriasis) at Screening Visit or Day 1 Other protocol-defined inclusion/exclusion criteria apply.